Healing at the Highest Level
In elite sport, the margin between competing and retiring can be a single injury. A torn tendon, a chronically inflamed joint, a compressed nerve — any one of these can derail a season or end a career that took a lifetime to build. For decades, surgery was the default response when conservative care fell short. What has changed significantly over the past decade is the emergence of regenerative medicine as a credible, evidence-supported alternative — one that harnesses the body's own biological capacity to reduce pain, restore tissue, and in many cases avoid surgery entirely. What makes this particularly relevant is not just what it has done for some of the most celebrated athletes in the world, but what it can do for the patients I see every day.
THE BASICS
What Regenerative Medicine Is and How It Works
Regenerative medicine refers to a category of biologic therapies that use materials derived from the patient's own body to stimulate tissue repair and reduce pathological inflammation. The two most clinically established options in musculoskeletal medicine are platelet-rich plasma and bone marrow aspirate concentrate. Platelet-rich plasma is prepared by drawing a small volume of the patient's blood, processing it to concentrate the platelet fraction, and injecting the resulting preparation into the target tissue under image guidance. Platelets are not simply clotting agents — they carry a dense payload of growth factors including PDGF, TGF-β, VEGF, and IGF-1 that initiate and regulate tissue repair cascades. Bone marrow aspirate concentrate, harvested from the patient's iliac crest and processed to concentrate mesenchymal stem cells alongside a rich growth factor milieu, provides a more potent biological stimulus for conditions involving more advanced tissue degeneration. Both therapies are autologous — meaning they come entirely from the patient's own body — which eliminates concerns about rejection or foreign material. Both are delivered as outpatient procedures under image guidance to ensure precise placement at the target tissue.
CLINICAL EVIDENCE
What Elite Athletes Have Demonstrated — and What the Research Confirms
Some of the most instructive examples of regenerative medicine in practice come from athletes whose careers depended on finding a solution that worked. Cristiano Ronaldo, facing chronic patellar tendinopathy in 2016 that was limiting his explosiveness and stability on the pitch, chose PRP therapy over surgery. He recovered and went on to lead Portugal to the European Championship that year. Kobe Bryant, dealing with chronic knee degeneration that threatened to end his career with the Los Angeles Lakers, pursued autologous conditioned serum therapy — a biologic approach conceptually similar to PRP — in Germany, and returned to compete at a high level for several additional seasons. Rafael Nadal, carrying both chronic knee tendinitis and lumbar spine pain accumulated over a career of elite tennis, underwent a course of PRP followed by autologous cell therapy and returned to form at the highest level of the sport. Hines Ward of the Pittsburgh Steelers sustained a significant MCL sprain weeks before Super Bowl XLIII, turned to PRP, recovered in time to play, and led his team in receiving during the championship game. Bartolo Colón, facing what appeared to be a career-ending combination of elbow and shoulder failure, underwent treatment using cells derived from his own bone marrow and adipose tissue and returned to pitch professionally — a case that drew significant national media attention to the potential of autologous biologic therapies.
These are not anecdotes selected to oversell a technology. They are illustrations of a biological principle that the clinical literature increasingly supports: that concentrated autologous growth factors, delivered precisely to damaged tissue, can accelerate repair and reduce inflammation in ways that passive rest and anti-inflammatory medication cannot replicate. The evidence base for PRP in tendinopathy, osteoarthritis, and soft tissue injury has grown substantially, with multiple randomized controlled trials demonstrating superiority over corticosteroid injection for conditions including lateral epicondylitis, patellar tendinopathy, and knee osteoarthritis at medium and long-term follow-up.
PATIENT SELECTION
Who Benefits From Regenerative Medicine
You do not need to be a professional athlete to benefit from regenerative medicine, and the conditions that respond best are among the most common I treat in clinical practice. PRP is well-suited for tendon injuries including rotator cuff tendinopathy, Achilles tendinopathy, patellar tendinopathy, and lateral epicondylitis; for early to moderate joint osteoarthritis of the knee, hip, and shoulder; for ligament injuries where surgical repair is not required; and for certain spinal applications including intradiscal injection for discogenic pain and facet joint augmentation. BMAC is considered for patients with more advanced degenerative changes where PRP may provide insufficient regenerative stimulus, or where the clinical picture suggests that a richer cellular environment is needed to drive a meaningful tissue response. As with all interventional procedures, precise patient selection and diagnostic accuracy are the primary determinants of outcome. A careful clinical evaluation and imaging review are essential before any regenerative treatment is recommended — these are not therapies to be applied broadly or without a clear structural diagnosis driving the decision.
All regenerative procedures at Osso Health are performed under image guidance — ultrasound, fluoroscopy, or both depending on the target — to ensure that the biologic is delivered precisely to the tissue that needs it. Precision of delivery is not incidental. It is a primary determinant of whether the therapy works.
FOR REFERRING CLINICIANS
Regenerative medicine represents a meaningful addition to the nonoperative management of musculoskeletal conditions, particularly for patients who have failed conventional injections including corticosteroids, who are seeking to avoid or delay surgery, or who have conditions where the evidence supports biologic therapy as a superior long-term option. I offer comprehensive evaluation to confirm candidacy, image-guided PRP and BMAC procedures for tendon, joint, and spinal indications, and clear documentation of findings, technique, and follow-up plan back to the referring provider. I welcome direct physician-to-physician consultation.
PERSPECTIVE
A Note on Regenerative Medicine Done Honestly
Regenerative medicine has generated significant excitement and, in some corners of medicine, significant overreach. Clinics offering unproven cell therapies for conditions where the evidence is absent, at prices that exploit desperate patients, have created a credibility problem for a field that has genuine and growing scientific support when applied appropriately. My position is straightforward: I use these therapies where the evidence supports them, in patients who are correctly selected, with preparations and techniques that reflect the published literature on what actually produces clinical benefit. I do not offer regenerative medicine as a universal solution or as an alternative to treatments that are more appropriate for a given patient's diagnosis. What I can offer is an honest assessment of whether a biologic therapy is likely to help, what the realistic expectations for outcome are, and how it fits within a comprehensive treatment plan designed around the patient's specific goals. For the right patient, at the right stage of their condition, PRP and BMAC represent some of the most exciting tools available in nonoperative musculoskeletal medicine. That is worth knowing about — and worth doing right.
DISCLOSURE & REFERENCES
This article is for educational purposes and reflects clinical experience and interpretation of published literature. It is not a substitute for individualized medical evaluation. Key references: Mishra AK et al. 2014 (PRP for lateral epicondylitis, Am J Sports Med); Filardo G et al. 2015 (PRP for knee OA, Knee Surg Sports Traumatol Arthrosc); Gosens T et al. 2011 (PRP vs corticosteroid for epicondylitis, Am J Sports Med); Centeno CJ et al. 2011 (BMAC for musculoskeletal conditions, Pain Physician); Tuakli-Wosornu YA et al. 2016 (intradiscal PRP, PM&R); Le ADK et al. 2019 (PRP for tendinopathy systematic review, Am J Sports Med).
ABOUT THE AUTHOR
Dr. Mahajer is a double board-certified physiatrist and sports medicine physician, fellowship-trained in Interventional Spine & Sports Medicine at the Icahn School of Medicine at Mount Sinai. He is an Assistant Professor of Neuroscience at FIU Herbert Wertheim College of Medicine. He is the Immediate Past President of the American Osteopathic College of Physical Medicine and Rehabilitation (AOCPMR), holds medical licenses in Florida, New York, and California, and has been recognized as a Top Physiatrist and Top Doctor in both Florida and New York.
